Biggest Battles in Biopharma

You know the picture: Two pharma CEOs, shaking hands and smiling as cameras flash and video rolls. It's been common enough, especially recently, as Pfizer and Wyeth, Merck and Schering-Plough announced their big mergers.

But that's not always the way M&A goes. While many pharma deals over the past 20 years have been relatively friendly, others haven't. Hostile bids, media grandstanding, warring press releases--unfriendly mergers have triggered them all.

The following list includes some of the biggest battles of the last two decades. We've covered a few of them ourselves, but others are before our time, such as Pfizer's Warner-Lambert takeover. Click below to get all the details on some of the industry's biggest takeover battles.
Click here to get started 

1. Sun Pharma vs. Taro
2. Pfizer vs. Warner-Lambert
3. Aventis vs. Sanofi-Synthelabo
4. Astellas Pharma vs. OSI Pharmaceuticals
5. King Pharmaceuticals vs. Alpharma
6. Novartis vs. Alcon
7. BMS vs. Icahn
8. Genzyme vs. Icahn

Read more on

Suggested Articles

In a departure from the usual approval process, the FDA says it doesn't require manufacturing inspections before weighing vaccines for emergency use.

Sanofi and Regeneron released follow-up data from a phase 3 trial for immunology blockbuster Dupixent in an eosinophilic esophagitis.

Singapore has suspended the use of two flu vaccines, from SK Bioscience and Sanofi, amid reports of deaths in South Korea after immunization.